Compounded Semaglutide: What You Need to Know
Compounded semaglutide costs a fraction of Ozempic or Wegovy. The savings are real. So are the risks — and the FDA has been explicit about both. This page covers what compounded semaglutide is, what the FDA says about it, and what your options are.
FDA Safety Warning
Compounded semaglutide is not FDA-approved and is not the same product as Ozempic or Wegovy. The FDA has documented serious safety concerns with compounded GLP-1 products, including:
- Incorrect potency and dosing
- Contamination and sterility failures
- Use of semaglutide sodium (a different salt form than the FDA-approved product)
- Products not tested for strength, purity, or quality
What is compounded semaglutide and is it safe?
Compounded semaglutide is a version of semaglutide mixed by a compounding pharmacy, not manufactured by Novo Nordisk. It costs $150-$500/month compared to $900-$1,500/month for brand-name products. It is not FDA-approved, has not undergone the same quality controls, and the FDA has issued warnings about safety concerns including incorrect potency, contamination, and use of a different salt form.
Compounding pharmacies are legally allowed to produce compounded semaglutide only during FDA-declared drug shortages. When the shortage ends, they must stop. The FDA does not verify the quality of compounded drugs the way it does for approved medications. If you are considering compounded semaglutide, discuss the risks with your healthcare provider.
Overview
What Is Compounded Semaglutide?
Compounded semaglutide is produced by compounding pharmacies — facilities that mix medications to order, rather than manufacturing them at scale like pharmaceutical companies. These pharmacies create their own formulations using semaglutide as an active ingredient, but the final product is not identical to Ozempic or Wegovy.
How It Differs from Brand-Name
- Not manufactured by Novo Nordisk
- Not FDA-approved or FDA-reviewed
- May use a different salt form (semaglutide sodium)
- Not subject to the same manufacturing controls
- Quality varies between compounding pharmacies
Legal Status
- Legal only during FDA-declared drug shortages
- Must be prescribed by a licensed provider
- Compounding pharmacies operate under 503A or 503B
- Status can change when shortages resolve
- Not covered by insurance
Safety
FDA Documented Safety Concerns
The FDA has been clear and specific about the risks of compounded semaglutide.
Incorrect Potency
The FDA has found compounded semaglutide products with incorrect concentrations of the active ingredient. Too much can cause dangerous side effects; too little means the drug will not work as expected. Brand-name manufacturers test every batch; compounders are not held to the same standard.
Semaglutide Sodium vs. Semaglutide Base
Some compounding pharmacies use semaglutide sodium instead of semaglutide base (the form used in Ozempic and Wegovy). These are different chemical entities. Semaglutide sodium has not been studied in clinical trials, and its safety and efficacy profile is unknown. The FDA has flagged this as a significant concern.
Sterility and Contamination
Injectable medications require strict sterile manufacturing. The FDA has documented contamination issues at compounding pharmacies producing semaglutide. Contaminated injectables can cause infections, including serious bloodstream infections.
No FDA Quality Oversight
FDA-approved drugs undergo rigorous manufacturing inspections, batch testing, and quality controls. Compounded drugs do not undergo this level of oversight. State boards of pharmacy regulate compounders, but the standards are less stringent than FDA manufacturing requirements.
Sources: FDA Safety Communication on Compounded Semaglutide, FDA Compounding Safety Information
Cost
Compounded vs. Brand-Name: Cost Comparison
| Option | Monthly Cost | FDA Approved | Insurance Eligible |
|---|---|---|---|
| Compounded semaglutide | $150-$500 | No | No |
| Ozempic (brand) | $900-$1,200 | Yes | Yes (diabetes) |
| Wegovy (brand) | $1,300-$1,500 | Yes | Yes (weight loss, if covered) |
| Ozempic with savings card | $25-$150 | Yes | Required |
| Novo Nordisk PAP (free) | $0 | Yes | Must be uninsured |
Prices are approximate monthly costs as of March 2026.
Alternatives
Safer Alternatives to Compounded Semaglutide
Manufacturer savings cards
Both Novo Nordisk and Eli Lilly offer savings cards that can reduce GLP-1 copays significantly for commercially insured patients. These work with FDA-approved products.
Patient assistance programs
If you are uninsured and meet income requirements, Novo Nordisk and Eli Lilly provide their brand-name medications at no cost through patient assistance programs.
Appeal a denial
If your GLP-1 was denied by insurance, over half of appeals succeed. A letter of medical necessity from your prescriber can save you the full retail price by getting your plan to cover the brand-name drug.
Ask about tirzepatide
Mounjaro and Zepbound (tirzepatide) are alternatives that may have different formulary placement. Your insurer may cover one but not the other.
Talk to your employer
If your plan excludes anti-obesity medications, the decision was made by your employer, not the insurance company. Employers can add AOM coverage for future plan years.
GLP-1 Medication Denied by Insurance?
You have the right to appeal. Our AI-powered appeal tool generates professional appeal letters with PubMed-cited evidence in minutes.
Compounded Semaglutide FAQs
Is compounded semaglutide the same as Ozempic or Wegovy?
No. Compounded semaglutide is mixed by a compounding pharmacy and is not the same product as Ozempic or Wegovy. It is not FDA-approved, has not undergone the same manufacturing quality controls, and may use a different salt form (semaglutide sodium vs. semaglutide base). The FDA has documented quality concerns including incorrect potency and contamination at some compounding pharmacies.
Is compounded semaglutide legal?
Compounded semaglutide is legal only during official FDA-declared drug shortages. Under federal law (section 503A and 503B of the FD&C Act), compounding pharmacies can produce copies of drugs that are on the FDA shortage list. When the shortage ends, compounding pharmacies must stop producing that drug. The legal status can change with little notice.
How much does compounded semaglutide cost?
Compounded semaglutide typically costs $150-$500 per month, compared to $900-$1,500/month for brand-name Ozempic or Wegovy. The lower cost is because compounders do not have the research, clinical trial, and FDA approval expenses that brand manufacturers carry. However, the lower cost comes with real quality and safety trade-offs.
What are the FDA warnings about compounded semaglutide?
The FDA has issued multiple warnings about compounded semaglutide. Documented concerns include: incorrect dosing/potency, contamination, use of semaglutide sodium (a different salt form than the FDA-approved semaglutide base), and products that have not been tested for sterility, strength, or purity. The FDA does not verify the quality of compounded drugs.
What happens when the semaglutide shortage ends?
When the FDA removes semaglutide from the shortage list, compounding pharmacies are required to stop producing compounded semaglutide. Patients on compounded versions would need to transition to brand-name semaglutide (Ozempic or Wegovy) or another GLP-1 medication. This transition may involve supply disruptions and significantly higher costs.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. MedicalRecords.com does not sell medications, endorse compounding pharmacies, or recommend compounded semaglutide. The FDA has documented safety concerns with compounded versions of semaglutide. Always consult your healthcare provider about treatment options.
Sources: FDA: Compounded Semaglutide Safety, FDA Drug Shortage Database, NIH DailyMed